Indian Journal of Urology最新文献_第6页

Medullary pyramids opacification in high-grade vesicoureteral reflux associated with posterior urethral valve 伴有后尿道瓣膜的高级别膀胱输尿管反流的髓质金字塔不透明

IF 1.1

Indian Journal of Urology Pub Date : 2023-12-29 DOI: 10.4103/iju.iju_316_23

S. Pandit, Yash Banait, Akshay Mahesh Kriplani

引用次数: 0

Is rucaparib the definite direction for metastatic prostate cancer? – TRITON3 results decoded 鲁卡帕尼是治疗转移性前列腺癌的明确方向吗？- TRITON3 结果解码

IF 1.1

Indian Journal of Urology Pub Date : 2023-12-29 DOI: 10.4103/iju.iju_373_23

Abhijit S. Shah

引用次数: 0

Round up 综述

IF 1.1

Indian Journal of Urology Pub Date : 2023-12-29 DOI: 10.4103/iju.iju_472_23

S. Mandal

引用次数: 0

Evaluation of a novel augmented reality educational tool and its effects on patient experience: A randomized controlled trial 评估新型增强现实教育工具及其对患者体验的影响：随机对照试验

IF 1.1

Indian Journal of Urology Pub Date : 2023-12-29 DOI: 10.4103/iju.iju_191_23

Caroline A. Miller, Rachel A. Locke, Hailey W. Holck, Holt J. Evans, Tiag P. Bhamber, Alexander L. Sinks, Lila G. McGrath, Danielle M. Boselli, Peter E. Clark, Ornob P. Roy

{"title":"Evaluation of a novel augmented reality educational tool and its effects on patient experience: A randomized controlled trial","authors":"Caroline A. Miller, Rachel A. Locke, Hailey W. Holck, Holt J. Evans, Tiag P. Bhamber, Alexander L. Sinks, Lila G. McGrath, Danielle M. Boselli, Peter E. Clark, Ornob P. Roy","doi":"10.4103/iju.iju_191_23","DOIUrl":"https://doi.org/10.4103/iju.iju_191_23","url":null,"abstract":"Patient education is an essential element of the treatment pathway. Augmented reality (AR), with disease simulations and three-dimensional visuals, offers a developing approach to patient education. We aim to determine whether this tool can increase patient understanding of their disease and post-visit satisfaction in comparison to current standard of care (SOC) educational practices in a randomized control study. Our single-site study consisted of 100 patients with initial diagnoses of kidney masses or stones randomly enrolled in the AR or SOC arm. In the AR arm, a physician used AR software on a tablet to educate the patient. SOC patients were educated through traditional discussion, imaging, and hand-drawn illustrations. Participants completed pre- and post-physician encounter surveys adapted from the Press Ganey® patient questionnaire to assess understanding and satisfaction. Their responses were evaluated in the Readability Studio® and analyzed to quantify rates of improvement in self-reported understanding and satisfaction scores. There was no significant difference in participant education level (P = 0.828) or visit length (27.6 vs. 25.0 min, P = 0.065) between cohorts. Our data indicate that the rate of change in pre- to post-visit self-reported understanding was similar in each arm (P ≥ 0.106 for all responses). The AR arm, however, had significantly higher patient satisfaction scores concerning the educational effectiveness and understanding of images used during the consultation (P < 0.05). While AR did not significantly increase self-reported patient understanding of their disease compared to SOC, this study suggests AR as a potential avenue to increase patient satisfaction with educational tools used during consultations.","PeriodicalId":47352,"journal":{"name":"Indian Journal of Urology","volume":"19 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139147909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human epidermal growth factor receptor 2/neu expression in urothelial carcinomas 尿路上皮癌中人类表皮生长因子受体 2/neu 的表达

IF 1.1

Indian Journal of Urology Pub Date : 2023-12-29 DOI: 10.4103/iju.iju_287_23

A. Soudamini, A. Nalwa, G. Choudhary, J. Bharti, M. Rao, P. Elhence, Himanshu Pandey, A. Goel

{"title":"Human epidermal growth factor receptor 2/neu expression in urothelial carcinomas","authors":"A. Soudamini, A. Nalwa, G. Choudhary, J. Bharti, M. Rao, P. Elhence, Himanshu Pandey, A. Goel","doi":"10.4103/iju.iju_287_23","DOIUrl":"https://doi.org/10.4103/iju.iju_287_23","url":null,"abstract":"Urothelial carcinomas of the bladder are more common in males, making them the sixth-most common cancer in men and the tenth-most common cancer overall, worldwide. Current guidelines do not recommend routine testing for human epidermal growth factor receptor (HER2/neu) expression on the biopsy specimens of patients with urothelial carcinoma. This study was aimed at determining the expression pattern of HER2/neu and its usefulness in muscle-invasive and nonmuscle-invasive urothelial carcinoma. HER2/neu expression was assessed in 89 specimens of urothelial cancer by immunohistochemistry (IHC), and equivocal cases were subjected to fluorescent in situ hybridization (FISH). On IHC for HER2/neu, 17.9% (7/39) of the muscle-invasive bladder cancers (MIBCs) showed a 3+ expression, whereas 22% (11/50) of the non-muscle invasive cancers were positive with a score of 3+. A significant correlation between HER2/neu status and muscle invasion could not be established in the current study (P = 0.74, Fisher’s exact test). Three cases of muscle-invasive (7.7%) and 2 cases (4%) among nonmuscle invasive cancers showed equivocal expression. All the cases with equivocal (2+) expression on IHC were subjected to FISH and none showed gene amplification on hybridization and were considered as negative. Overexpression of HER-2/neu was seen in 17.9% of MIBCs and 22% of non-MIBCs. There are no norms for routine testing of HER2/neu expression in the biopsy specimens of urothelial carcinoma. There is an unmet need to establish guidelines for HER2/neu scoring, similar to that for breast and gastric cancers, to determine the proportion of positive cases and help in identification of those who may benefit from targeted therapies.","PeriodicalId":47352,"journal":{"name":"Indian Journal of Urology","volume":" 26","pages":""},"PeriodicalIF":1.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139143835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fifteen-year outcomes of the ProtecT trial: Should patients be "protected" from radical treatments? ProtecT 试验的 15 年结果：是否应 "保护 "患者免于接受根治性治疗？

IF 1.1

Indian Journal of Urology Pub Date : 2023-10-01 Epub Date: 2023-09-29 DOI: 10.4103/iju.iju_271_23

Nisanth Puliyath